Insulet lures Analogic CFO Levitz | Personnel Moves

Insulet (NSDQ:PODD) today said it’s replacing its CFO with the finance chief at Analogic (NSDQ:ALOG), Michael Levitz.

Levitz is slated to succeed Allison Dorval, who’s stepping down "to pursue other professional opportunities," effective May 4, Billerica, Mass.-based Insulet said.

Dorval, who’s been at Insulet since 2008, was controller there when she replaced Brian Roberts last fall. She’s slated to stay on through July 3 to help with the transition, the company said.

"We are grateful to Allison for her many years of service to Insulet. We wish her well in her future endeavors," president & CEO Patrick Sullivan said in prepared remarks.

"Mike has an exceptional work ethic, a deep understanding of the medical device sector and a proven track record of success," Sullivan added. "I am confident he brings the experience and skills to take the Insulet finance team to the next level. His expertise leading global finance organizations will be valuable to the company as we continue to grow our U.S. and international diabetes businesses and capitalize on exciting opportunities to leverage Insulet’s drug delivery technology in new therapeutic areas. Our senior leadership team is focused on executing our strategy to position Insulet for sustained accelerated growth over the long-term, and Mike’s extensive public company CFO experience will significantly enhance our capabilities."

For its part, Analogic said its controller, Michael Bourque, will serve as interim CFO while the Peabody, Mass.-based company looks for a replacement.

"Mike Levitz has been a key member of our senior leadership team during his tenure with our company. Through his efforts, we have developed a strong finance organization that is integral to our company’s success. We wish Mike the very best as he pursues a unique opportunity and enters the next phase of his career," president & CEO Jim Green said in a statement.

"I am very pleased to have the opportunity to work with Pat and the Insulet team. I believe the OmniPod is a truly innovative and differentiated drug delivery platform which not only has the potential to continue winning market share across the global insulin pump market, but also to expand meaningfully into additional drug delivery opportunities, positioning Insulet for long-term growth. I look forward to contributing to Insulet’s success," Levitz said.

 Align Technology CEO Prescott to retire

Align Technology (NSDQ:ALGN)
CEO Thomas Prescott is slated to retire effective June 1, to be replaced by former ABB Ltd. CEO Joseph Hogan. Prescott is set to continue to serve on Align’s board, the company said.

 Reva Medical taps ex-Volcano CEO Huennekens for board
Reva Medical (ASX:RVA) said it tapped the former CEO of Volcano, Scott Huennekens, for a seat on its board of directors. Royal Philips (NYSE:PHG) agreed to pay $1.2 billion for Volcano late last year.
Read more

 Benvenue Medical’s new CFO is a Volcano vet too
Benvenue Medical also nabbed a former Volcano executive, naming former finance chief John Dahldorf to be Benvenue’s new CFO.
Read more